MyeCellTherapy: A novel myeloid-based cell therapy for glioblastoma, using genetically enhanced iPSCs-derived macrophages (iGEMs).

Project Details

Description

Glioblastoma (GBM) is the most prevalent and aggressive form of
primary brain tumors. GBM is currently incurable, representing a
major socioeconomic burden and unmet medical need. Whilst cancer
immunotherapies have revolutionized oncology treatment, many
cancers (including GBM) remain unresponsive to immunotherapy due
to their low frequency of T lymphocytes and high infiltration of tumorassociated
macrophages (TAMs). However, the possibility to target
and re-educate these TAMs forms a promising next frontier in cancer
immunotherapy. The MyeCellTherapy project proposes the
development of a novel myeloid-based cell therapy for cancers that
are unresponsive to current T cell-based approaches. The concept
relies on the depletion of immunosuppressive TAMs within the tumor
and their immediate replacement with genetically enhanced iPSC-derived
macrophage counterparts (iGEMs), which have been
enhanced in such a way that they promote anti-tumor immunity. The
MyeCellTherapy project thus aims to lay the foundations for a new
personalized myeloid-based immunotherapy approach for low
immunogenic cancers.
AcronymFWOTM1105
StatusNot started
Effective start/end date1/10/2230/09/25

Flemish discipline codes

  • Adaptive immunology
  • Cancer biology
  • Neurosciences not elsewhere classified

Keywords

  • Myeloid-based immunotherapy
  • iPSC-derived macrophages
  • Glioblastoma multiforme